Grants for For profit organizations other than small businesses - Science and Technology

This grant provides funding to early-career researchers dedicated to innovative breast cancer research, emphasizing transformative approaches and collaboration with breast cancer survivors.

Maturing research ideas into clinical practice and patient benefit is at the heart of all CDMRP research programs. Despite significant investment, the gap between what is possible and what is achieved remains. Even after information, tools, and interventions have been successfully evaluated in their intended populations, the development of knowledge to support their broader dissemination and implementation has often remained outside the scope. The FY24 TBIPHRP HSRA intends to bridge the gap between research, practice, and policy by building real-world evidence on how interventions, clinical practices/guidelines, and policies can be deployed to targeted populations at the appropriate time.Research Scope: The FY24 HSRA will fund clinical research (including clinical trials). Preclinical and animal research are prohibited. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed. Proposed clinical trials should include interventions, clinical practices/guidelines, and policies that are well-supported within the literature and in relevant patient population(s). This award may not be used to support studies requiring an exception from informed consent (EFIC).Key aspects of the FY24 TBIPHRP HSRA: Precision Medicine Approaches: When appropriate, the TBIPHRP encourages the use of precision medicine approaches. These tailored treatments deliver the right treatment at the right time while considering an individuals unique characteristics. Community-Based Participatory Research: The application must include Community-Based Participatory Research (CBPR) approaches in the development and execution of the clinical research/trial. CBPR approaches should be documented in Attachment 8. Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical research/trial is required. Untested novel interventions are discouraged: Novel interventions that have not been evaluated in the intended population(s) are discouraged. Applicants seeking funding for novel interventions should consider one of the other FY24 TBIPHRP announcements. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Inquiry Review Board [IRB] review) are exempt from this requirement. Clinical Trial Start Date: If applicable, the proposed clinical trial is expected to begin no later than 6 months after the award date. Intervention Availability: If applicable, the application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.The FY24 HSRA applications may include (not all inclusive): Research that accelerates the uptake and implementation of evidence-based research into clinical practice. Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings. Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. Analysis of existing data or resources to inform clinical practice. Modification of established clinical tools for their intended population or environment. Analysis of existing clinical tools to maximize patient-relevant outcomes. Identification and analysis of the circumstances that create a need to stop or reduce (de-implement) the use of interventions, tools, policies, and guidelines that are ineffective, unproven, low-value, or harmful are within scope. Analysis of TBI and/or psychological health outcomes associated with the implementation of clinical practice guidelines, evidence-based practices, and process improvements.Early-Career Investigator Partnering Option: The FY24 TBIPHRP HSRA includes an Early-Career Investigator Partnering Option that is structured to accommodate two Principal Investigators (PIs), one of whom is an Early-Career Investigator. The combined direct costs budgeted for the entire period of performance in the applications of the Initiating PI and Partnering PI should not exceed $2.5M. The PIs may have experience in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. One PI will be identified as the Initiating PI and will be responsible for most of the administrative tasks associated with application submission. The other investigator will be the Partnering PI. At least one of the Initiating or Partnering PIs must be an Early-Career Investigator. The intent is not to create mentor-mentee arrangement. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The application is expected to describe how the PIs unique experience/expertise combined as a partnership will better address the research question, how the unique experience/expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. If recommended for funding, each PI will be named to an individual award within the recipient organization(s). For individual FY24 TBIPHRP HSRA submission requirements for the Initiating and Partnering PI, refer to S Section II.D.2, Content and Form of the Application Submission.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document.pdf.Clinical trials may be designed to evaluate pharmacologic agents (drugs or biologics), diagnostics, devices, therapies, clinical guidance, behavioral interventions, emerging approaches and technologies, and/or new indications for products currently U.S. Food and Drug Administration (FDA)-approved or -cleared. Interventions that are not FDA-regulated (or international equivalent) are within scope but the regulatory status must be documented in Attachment 12, Regulatory Strategy.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Multi-Institutional Clinical Research/Trials: As of January 20, 2020, U.S. institutions engaged in non-exempt cooperative research must rely on a single IRB to review and approve the portion of the research conducted at domestic sites (45 CFR 46.114(b)). If the proposed, non-exempt research involves more than one U.S.-based institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.Communication and data transfer between or among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the application. A separate intellectual and material property plan agreed on by all participating institutions is also required for multi-institutional clinical research/trials.Relevance to Military Health: Relevance to the health care needs of Service Members, their Families, and Veterans is a key feature of this award. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health: Explanation of how the project addresses an aspect of psychological health conditions and/or TBI that has direct relevance to the health and/or readiness of Service Members, their Families, and Veterans. Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to benefit the civilian population and also address a military need. Use of military or Veteran populations, samples, or datasets in the proposed research, if appropriate.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $15.5M to fund approximately four HSRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This grant provides funding for researchers and organizations to analyze data from Mars missions, supporting advancements in our understanding of the planet's geology, climate, and potential for life.

This grant provides financial support to San José-based nonprofit arts and cultural organizations that promote community engagement and contribute to the city's cultural vitality through diverse artistic programming.

This program provides funding and support to small businesses in Pennsylvania that are historically disadvantaged, helping them access capital and improve their participation in public contracts.

The FY24 PCRP Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are: Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Projects involving multidisciplinary and/or data science approaches are especially encouraged. Impact: Applications are required to address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the FY24 PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Preliminary Data: Due to this awards emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data are included, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.New Investigator category: The FY24 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers. The New Investigator category of this award mechanism is designed to allow applicant organizations to name PIs who are early in their faculty appointments or in the process of developing independent research careers. Applications submitted to the New Investigator category will be assessed using different review criteria for personnel (refer to Section II.E.1.a., Peer Review) and are required to include a collaborator (or collaborators) who has (have) experience in prostate cancer research, as demonstrated by a record of funding and publications. The application must describe the potential of the collaboration(s) to be successful and how the collaboration(s) will augment the PIs expertise to better address the research question. In addition, applicants are strongly encouraged to provide a letter of collaboration from the collaborator(s) describing the collaborator(s) involvement in the proposed work. All applicants for the New Investigator category must meet specific eligibility criteria described in Section II.C, Eligibility Information.Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include a clearly stated plan for interactions among all team members and organizations involved. The plan must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Idea Development Award should not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $53.76M to fund approximately 28 Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports innovative scientific research and technology development relevant to maritime applications, inviting proposals from academia, industry, and research institutions, including Historically Black Colleges and Universities and Minority Institutions.

This funding opportunity supports not-for-profit organizations and local governments in New York State to provide food boxes and nutrition education in communities eligible for SNAP benefits.

This grant provides funding for collaborative research teams of independent investigators to advance innovative solutions in melanoma prevention, treatment, and survivorship, with a focus on improving patient outcomes.

This program provides free technical assistance to small Pennsylvania businesses to help them improve their operations and competitiveness by connecting them with expert resources and solutions for specific technical challenges.

The DoD Tick-Borne Disease, Idea Development Award is a grant aimed at funding innovative research that could significantly advance the understanding and treatment of Lyme disease and other tick-borne diseases, ultimately improving the lives of military personnel, veterans, their families, and the general public.

This funding supports Colorado newsrooms in organizing community engagement events to connect with diverse local residents, address their concerns, and foster trust between journalists and the communities they serve.

The Haywood County Tourism Development Authority (HCTDA) Grant program for 2024-2025 aims to financially support initiatives that enhance tourism within Haywood County, North Carolina. This program is sustained by room tax revenue, directly aligning the grant's mission with the economic development and visitor attraction goals of the region. By investing these funds back into the tourism sector, HCTDA seeks to bolster local businesses and non-profit organizations that contribute to the county's appeal as a destination. The grant targets a diverse range of beneficiaries, including non-profit organizations, for-profit businesses, museums, attractions, cultural events, and governmental agencies. Eligibility criteria vary slightly between the two main grant categories: Legacy Event Sponsorship and Tourism Promotion Grant. Legacy Event Sponsorship is open to a broader array of entities that have a proven track record of drawing visitors, while the Tourism Promotion Grant is primarily for non-profit organizations, museums, attractions, and governmental agencies, with a specific provision for for-profit tourism-based organizations with a 100% grant match. The program's core priorities and focuses are to attract visitors from outside a fifty (50) mile radius and to generate overnight stays, thereby creating economic and destination impact. Preference is given to applications that demonstrate a strong potential to achieve these outcomes. This strategic focus ensures that the grant funds are utilized to maximize external visitor engagement and directly contribute to the county's tourism economy, while also enhancing the quality of life for local residents. Expected outcomes and measurable results include increased visitor numbers, extended stays, and a stronger overall tourism image for Haywood County. The grant program seeks to support innovative campaigns, advertising efforts, and promotional activities that effectively reach target markets. Successful applications will demonstrate how their initiatives will not only attract tourists but also showcase the unique aspects of Haywood County and its communities, leading to sustained economic benefits. The HCTDA's strategic priorities are rooted in leveraging room tax revenue to cultivate a vibrant and robust tourism industry. Their theory of change posits that by providing targeted financial support for established events and promotional initiatives, they can directly stimulate visitor traffic, encourage overnight stays, and foster a positive economic ripple effect throughout the county. This approach ensures that the grant program acts as a catalyst for growth, continually reinforcing Haywood County's position as a desirable tourist destination.

This funding opportunity is designed to support innovative citizen science projects that engage the public in space and Earth science research, encouraging collaboration between scientists and community members.

This program provides funding to support community events that promote cultural and economic development in Lawrence, Kansas, enhancing the city's unique identity.

This program provides support, mentorship, and funding to early-stage cleantech startups in Tennessee and surrounding regions to help them commercialize innovative technologies.

This program provides funding to nonprofit housing developers for the acquisition and demolition of deteriorated properties to facilitate the construction of new residential developments in aging neighborhoods.

First Literacy awards grants to stimulate and support the development, trial, and implementation of innovative Adult Basic Education and English for Speakers of Other Languages resources and practices in Massachusetts. The program invests in ideas that improve educational and professional outcomes for adult learners and that may not be eligible for state or other major funding. Grant types include Program Grants for project based innovations, Organization Wide Grants for larger scale curricula, systems, training, or teacher improvement, and Incentive Grants for second year replication or for assisting another organization to replicate a program. Program grant caps are generally 5,000 dollars for returning organizations and 7,500 dollars for organizations that have not received funding in the past ten years. Organization Wide Grants are up to 15,000 dollars and include robust data reporting plans. The grant period is July 1, 2024 through June 30, 2025. Projects should demonstrate lasting impact in ABE schools and organizations and include clear evaluation and data collection plans. Eligibility is open to not for profit ABE and ESOL organizations in Massachusetts. Applications are due May 2, 2024. Additional information is available from First Literacy.

This grant provides funding for researchers studying ancient sediments and fossils to better understand the Earth's history, environmental changes, and the evolution of life before the Holocene epoch.

The Federal and State Technology (FAST) Partnership Program provides funding to organizations to execute state/regional programs that increase the number of SBIR/STTR proposals leading to an increase in the number of SBIR/STTR awards from women, socially/economically disadvantaged individuals, and small businesses in underrepresented areas - typically rural states.